A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

Trial Details

NCT ID
NCT03110822
Phase
PHASE1
Sponsor
Oncotherapeutics
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Ruxolitinib Oral Tablet [Jakafi]
  • Lenalidomide
  • Methylprednisolone
Locations (sample)
  • Alhambra, California, United States|34.09529,-118.12701
  • Bakersfield, California, United States|35.37329,-119.01871
  • Encinitas, California, United States|33.03699,-117.29198
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Fountain Valley, California, United States|33.70918,-117.95367

Key Eligibility Criteria

  • Subjects must meet all of the following inclusion criteria to be eligible to enroll in this study.
  • 1\. Has a diagnosis of MM based on standard criteria as follows:
  • Major criteria:
  • Plasmacytomas on tissue biopsy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →